FDA Accepts NDA for Medivation's (MDVN) Enzalutamide; $10M Milestone Payment Triggered
Tweet Send to a FriendGet Alerts MDVN Hot Sheet
Up)
Trade MDVN Now!
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. announced the FDA has accepted for filing the NDA for enzalutamide (formerly MDV3100) for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy and granted Priority Review Designation.
The FDA's acceptance of the NDA triggers a $10 million milestone payment to Medivation under its Collaboration Agreement with Astellas.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The FDA's acceptance of the NDA triggers a $10 million milestone payment to Medivation under its Collaboration Agreement with Astellas.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Novo Nordisk (NVO) Reports Positive Results from Paradigm 2
- Illumina (ILMN) Announces Full Launch of BaseSpace
- St. Jude (STJ) Receives CE Mark for LUMIEN OPTIS PCI System
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
